COL1A1 and osteogenesis imperfecta: With an adeno-associated virus-mediated gene targeting strategy, Deyle et al. generated iPSC-MSCs derived from OI patients and subsequently inactivated the mutated COL1A1 and COL1A2 genes in the iPSC-MSCs.